Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.50 |
| ▸ | AHCY | P23526 | 3/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.49 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8306794 | 0.90 | ADORA3 (0.49) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL118827 | 0.86 | ADORA3 (0.69) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL5786575 | 0.85 | ADORA2A (0.48) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL121441 | 0.85 | ADORA3 (0.69) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL1078828 | 0.84 | ADORA2A (0.64) | ADORA3AHCYADORA2AADORA1ADORA2B | |
| SCHEMBL5987749 | 0.84 | ADORA2A (0.47) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL28156591 | 0.84 | ADORA2A (0.64) | ADORA3AHCYADORA2AADORA1ADORA2B | |
| SCHEMBL2294592 | 0.83 | ADORA3 (0.43) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL258929 | 0.82 | ADORA3 (0.59) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL122980 | 0.81 | ADORA1 (0.72) | ADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140100184-A1 | SELECTIVE INHIBITORS OF HISTONE METHYLTRANSFERASE DOT1L | BAYLOR COLLEGE OF MEDICINE (US) | 2014-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100184-A1 | SELECTIVE INHIBITORS OF HISTONE METHYLTRANSFERASE DOT1L | CARM1, DOT1L, PRMT1 | ADORA3 4058/4885AHCY 674/4885ADORA2A 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.